Zydus Lifesciences Limited
ZYDUSLIFE · Pharma · NSE
₹1,106
Current Market Price
Fair Value (DCF)
₹1,425
Discount to FV
+28.9%
Updated 1h ago
YieldIQ Score
63/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
50%
ROE
17.2%
Debt/Equity
0.12
WACC
10.5%
Market Cap
₹1.11 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
23.8%
Return on capital employed
EV / EBITDA
14.2×
Enterprise multiple
Debt / EBITDA
1.5×
Leverage vs earnings
Interest Coverage
16.1×
EBIT covers interest
Current Ratio
1.27×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
16.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,105.6
Bear case
Discount -29.9%
Base case
Discount +22.4%
Bull case
Discount +43.6%
Ratio Trends
ZYDUSLIFE · last 4 annual periods
ROE
17.2%
ROCE
23.8%
Operating Margin
—
Debt / Equity
0.12×
PE
25.2×
EV / EBITDA
14.6×
Historical Financials
ZYDUSLIFE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹14.8K Cr | ₹16.9K Cr | ₹19.0K Cr | ₹22.6K Cr | ₹26.7K Cr | +15.9% |
| EBITDA | ₹3689 Cr | ₹3438 Cr | ₹5617 Cr | ₹7108 Cr | ₹8468 Cr | +23.1% |
| EBIT | ₹2965 Cr | ₹2720 Cr | ₹4890 Cr | — | — | +13.3% |
| PAT | ₹4487 Cr | ₹1960 Cr | ₹3860 Cr | ₹4526 Cr | ₹5040 Cr | +2.9% |
| EPS (diluted) | ₹21.90 | ₹19.35 | ₹37.91 | — | — | +14.7% |
| CFO | ₹2105 Cr | ₹2689 Cr | ₹3196 Cr | ₹6781 Cr | ₹2117 Cr | +0.1% |
| CapEx | ₹-1203 Cr | ₹-1031 Cr | ₹-907 Cr | ₹-1694 Cr | ₹-2672 Cr | — |
| FCF | ₹902 Cr | ₹1658 Cr | ₹2290 Cr | ₹5087 Cr | ₹-555 Cr | — |
| Total Assets | ₹27.8K Cr | ₹25.8K Cr | ₹29.3K Cr | ₹37.2K Cr | ₹52.4K Cr | +17.2% |
| Total Debt | ₹4221 Cr | ₹1195 Cr | ₹804 Cr | ₹3213 Cr | ₹12.5K Cr | +31.2% |
| Shareholders' Equity | ₹17.0K Cr | ₹17.5K Cr | ₹19.8K Cr | ₹24.0K Cr | ₹27.1K Cr | +12.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ZYDUSLIFE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 CIPLA Cipla Limited | -11.5% | 45 | Near Fair Value | 11.3% | 25.5× |
 MANKIND Mankind Pharma Limited | -56.0% | 40 | Above Fair Value | 11.7% | — |
 DRREDDY Dr. Reddy's Laboratories Limited | +19.7% | 55 | Near Fair Value | 11.4% | 24.4× |
 LUPIN Lupin Limited | +35.6% | 50 | Near Fair Value | 23.8% | 19.8× |
 AUROPHARMA Aurobindo Pharma Limited | +6.7% | 56 | Near Fair Value | 9.3% | 21.4× |
Click a ticker to view its fair-value analysis.
Dividend History
9 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹26.00/sh
Last payout
2025-07-25
₹11.00
Peak payout
₹11.00
Trailing yield
0.99%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Zydus Lifesciences Limited (ZYDUSLIFE.NS) trades at 1105.60 vs a model fair value of 1425.09, a gap of 28.9%. Piotroski F-score: 5/9. Moa...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ZYDUSLIFE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ZYDUSLIFE →
Compare
Head-to-head with peers
Compare ZYDUSLIFE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ZYDUSLIFENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.